Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperyork Reduction Act of 1995 popersons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

TENTH SUPPLEM

MAR 1 6 2006

INFORMATION DISKS

STATEMENT BY APPLICAT (Use as many sheets as necessary)

Sheet of

Comple	te if Known	
Application Number	10/023,584	
Filing Date	December 21, 2001	
First Named Inventor	Rosen, Craig A.	
Art Unit	1647	

Examiner Name Landsman, Robert S. Attorney Docket Number 1488.100000Q/HCC/LMB

			U.S. PATENT DO	OCUMENTS	
Examiner Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines,	
IIIIIIais	140.	Number-Kind Code ^{2 (If Known)}	WIWI-DD-1111	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
BC	US5	5,652,225	07/29/1997	Isner	
	US6	5,661,133	08/26/1997	Leiden and Barr	
	US7	5,693,622	12/02/1997	Wolff et al.	
	US8	5,792,453	08/11/1998	Hammond et al.	
	US9	6,121,246	09/19/2000	Isner	
	US10	6,361,946 B1	03/26/2002	Alitalo and Joukov	
\checkmark	US11	6,451,764 B1	09/17/2002	Lee and Wood	
	ļ				

		Fo	REIGN PATENT DO	OCUMENTS		-
Examiner Cite Initials* No.1	Foreign Patent Document Country Code' Number' Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or		
		Country Code Number Kind Code (if known)			Relevant Figures Appear	Té
BC	FP24	EP 0 186 084 A2	07/02/1986	Merck & Co. Inc.		
	FP25	JP 64-38100 A	02/08/1989	Toray Ind. Inc.		
	FP26	JP 2-117698 A	05/02/1990	Ajinomoto KK and Toray Ind. Inc.		
- 1	FP27	EP 0 399 816 A1	11/28/1990	Merck & Co. Inc.		
	FP28	WO 94/11506 A1	05/26/1994	Arch Development Corporation		
	FP29	WO 00/45835 A1	08/10/2000	Human Genome Sciences, Inc. and Rosen et al.	·	
	FP30	WO 02/11769 A1	02/14/2002	Human Genome Sciences, Inc. and Coleman		
\bigvee	FP31	WO 02/083704 A1	10/24/2002	Human Genome Sciences, Inc. and Rosen et al.		

Everniner		Deta	
Examiner		Date	i
Signature	(Could	Considered	4.7.06
	Sector		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute f	or form	1449/PTC)	Complete	if Known		
TENT	теп	DDI E	MENTAL DISCLOSURE Application Filing Da First Nam Art Unit Examiner	Application Number	10/023,584		
				Filing Date	December 21, 2001		
				I That Isabled Historica	Rosen, Craig A.		
STATE	EME	NT BY	APPLICANT	Art Unit	1647		
((Use as	many she	ets as necessary)	Examiner Name	Landsman, Robert S.		
heet	2	of	2	Attorney Docket Number	1488.100000Q/HCC/LMB		
	TENTI INFOR STATE	FENTH SU INFORMA STATEME (Use as	FENTH SUPPLES INFORMATION STATEMENT BY (Use as many she	STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number Filing Date First Named Inventor Art Unit (Use as many sheets as necessary) Application Number Filing Date First Named Inventor Art Unit Examiner Name		

			U.S. PATENT DO	CUMENTS		
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Number-Kind Code ^{2 (If Known)}	_		or Relevant Figures A	
						
	ļ	-				-
	ļ					
	ļ					
			-			
	 				<u> </u>	
	l		OREIGN PATENT I	OCUMENTS	<u> </u>	
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns,	T
Initials*	No. ¹	Country Code ³ Number ⁴ Kind Code ³ (if known)	MM-DD-YYYY	Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
BC	FP32	WO 02/083849 A2	10/24/2002	Human Genome Sciences, Inc. and Rosen et al.		
	FP33	WO 02/083850 A2	10/24/2002	Human Genome Sciences, Inc. and Rosen et al.		
\downarrow	FP34	WO 03/097660 A1	11/27/2003	Human Genome Sciences, Inc. and Rosen et al.		
-	_		 			
						

504661_1.DOC

Examiner		Date	
Signature	Lourse	Considered	4.7.06

English language Transtation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and *EXAMINER: Initial if reference considered, whether or not citation is in conformance win MPEP bus. Draw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Finter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (07-05) Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Reduction Act of 1950/no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for fe	CNTH SUPPLEMENTAL FORMATION DISCLOSURE ATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known			
				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
(4	Jse as man	y sheets as	necessary)	Examiner Name	Landsman, Robert S.
Sheet	1	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

MAR 1 6 2006

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	$\overline{}$
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T
BL	NPL23	Borg, JP., et al., "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," Oncogene 10:973-984, Stockton Press (March 1995)	
	NPL24	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-01, Abstract (January 1994)	
	NPL25	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-02, Abstract (January 1995)	
	NPL26	Choi, I.H., et al., "Angiogenesis and Mineralization During Distraction Osteogenesis," J. Korean Med. Sci. 17:435-447, The Korean Academy of Medical Sciences (August 2002)	
	NPL27	Copy of Declaration of Dr. Kari Alitalo, In re of: U.S. Application No. 08/585,895, Alitalo et al., filed January 12, 1996, submitted November 26, 1997	
	NPL28	Dias, S., et al., "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," Blood 99:2179-2184, The American Society of Hematology (March 2002)	
	NPL29	English language abstract of JP 64-38100 A, cited as document FP25 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912	
	NPL30	English language abstract of JP 2-117698 A, cited as document FP26 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024	
	NPL31	Fan, TP.D., et al., "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmaco. Sci. 16</i> :57-66, Elsevier Science Ltd. (February 1995)	
\downarrow	NPL32	Isner, J.M., et al., "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," Circulation 91:2687-2692, American Heart Association, Inc. (June 1995)	

<u> </u>			
Examiner		Date	
		72.0	l
Signature	(/s/X1X	Considered	1 4.7.06
<u> </u>	2,0010] -7.7.06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for fo			non Net of 1999, the pers	Complete if Known			
TENTHS	riddi i		TTAT	Application Number	10/023,584		
				Filing Date	December 21, 2001		
	TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		First Named Inventor	Rosen, Craig A.			
				Art Unit	1647		
(((Use as many sheets as necessary)	s necessary)	Examiner Name	Landsman, Robert S.			
Sheet	2	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BL	NPL33	Isner, J.M. and Feldman, L.J., "Gene therapy for arterial disease," Lancet 344:1653-1654, The Lancet Ltd. (December 1994)	
	NPL34	Isner, J.M., et al., "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth Factor," J. Cell. Biochem. (Suppl. 21A):378, Abstract C6-215, Wiley-Liss (March-April 1995)	
	NPL35	Isner, J.M., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL53354-01, Abstract (March 1995)	
	NPL36	Kubo, H., et al., "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea," Proc. Natl. Acad. Sci. 99:8868-8873, The National Academy of Sciences (June 2002)	
	NPL37	Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell Differentiation in Vitro by Fibroblast-Derived Soluble Factors," Exp. Cell Res. 215:310-318, Academic Press, Inc. (December 1994)	
	NPL38	Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," <i>J. Cell. Physiol.</i> 151:549-554, Wiley-Liss, Inc. (1992)	
	NPL39	Mesri, E.A., et al., "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice," Circulation Res. 76:161-167, American Heart Association, Inc. (February 1995)	
	NPL40	Mühlhauser, J., et al., "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," Circulation 88:I-475, Abstract No. 2558, American Heart Association (October 1993)	
	NPL41	Mühlhauser, J., et al., "VEGF ₁₆₅ Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," Circulation Res. 77:1077-1086, American Heart Association, Inc (December 1995)	
V	NPL42	Oikawa, T., et al., "Three Isoforms of Platelet-Derived Growth Factors All Have the Capability to Induce Angiogenesis In Vivo," Biol. Pharm. Bull. 17:1686-1688, (December 1994)	

Examiner Signature	Cardal 8	Date Considered	4.7.06
Signature	Loed	Considered	7.7.06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not In conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO				Co	mplete if Known
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
1 -	STATEMENT BY APPLICANT			Art Unit	1647
(Use as many sheets as necessary)		Examiner Name	Landsman, Robert S.		
Sheet	3	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T²			
BL NPL43		Pajusola, K., et al., "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," Oncogene 9:3545-3555, Macmillan Press Ltd. (December 1994)				
	NPL44	Pepper, M.S., et al., "In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells," Exp. Cell Res. 210:298-305, Academic Press, Inc. (January 1994)				
	NPL45	Plate, K.H., "From angiogenesis to lymphangiogenesis," Nat. Med. 7:151-152, Nature America, Inc. (February 2001)				
	Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and treatment diabetic retinopathy," Exp. Clin. Endocrinol. Diabetes 109(Suppl. 2):S438-S456 J.A. Barth Verlag (2001)					
	NPL47	Symes, J.F. and Sniderman, A.D., "Angiogenesis: potential therapy for ischaemic disease," Curr. Opin. Lipidol. 5:305-312, Current Science Ltd. (August 1994)				
	NPL48	Takeshita, S., et al., "In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor," Circulation 88:I-476, Abstract No. 2565, American Heart Association (October 1993)				
	NPL49	Takeshita, S., et al., "Therapeutic Angiogenesis. A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," J. Clin. Invest. 93:662-670, The American Society for Clinical Investigation, Inc. (February 1994)				
	NPL50	Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res. 3</i> :147-153, BioMed Central Ltd. (February 2001)				
	NPL51	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," Am. J. Med. Sci. 306:129-136, Lippincott Williams & Wilkins (August 1993)				
√	NPL52	Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-				
Examiner Signature		Social Date Considered 4.7.06	_			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number.

Substitute for	Substitute for form 1449/PTO			Co	mplete if Known
TENTH	CTIDDI I	e name ni	TT A T	Application Number	10/023,584
TENTH				Filing Date	December 21, 2001
			CLOSURE	First Named Inventor	Rosen, Craig A.
1	STATEMENT BY APPLICANT			Art Unit	1647
(Use as many sheets as necessary)		Examiner Name	Landsman, Robert S.		
Sheet	4	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²					
BL	NPL53	Yeung, P.K.F., "VEGF-2," Curr. Opin. Invest. Drugs 2:796-800, PharmaPress Ltd. (June 2001)						
	-							
504665 1.D								

Examiner Date Signature 4.7.06 Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAP 1 6 2006

Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction vision of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form	1449/PT0	PAI	DEMARITE Complete	if Known	
TO T TO \$7	e sign	T CTID	DI PRAPRITAT	Application Number	10/023,584	
ELEVENTH SUPPLEMENTAL		Filing Date	December 21, 2001	_		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	Rosen, Craig A.	
				Art Unit	1647	_
	(Use as	many she	ets as necessary)	Examiner Name	Landsman, Robert S.	_
Sheet	1	of	1	Attorney Docket Number	1488.100000Q/HCC/LMB	_

			U.S. PATENT DO	CUMENTS	
Examiner Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No. ¹	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear
BL	US12	2006/0014252 A1	01/19/2006	Lyman	
			<u> </u>		
					
			+		
	-		 	· · · · · · · · · · · · · · · · · · ·	
	 		 	·	
	 				

	·	Fo	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ¹ Number ⁴ Kind Code ⁵ (if known)			Relevant Passages or Relevant Figures Appear	T ⁶
· -						\vdash
						\vdash
						\vdash

505842_1.DOC

			•
Examiner		Date	
Signature	Costol	Considered	4.7.06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO				Complete if Known		
	arri ei	IDDI E	AMERICA I	Application Number	10/023,584	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE				Filing Date	December 21, 2001	
				First Named Inventor	Rosen, Craig A.	
STATEMENT BY APPLICANT				Art Unit	1647	
(Use as many sheets as necessary)		Examiner Name	Landsman, Robert S.			
Sheet	1	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
BU NPL54		Danis, R.P., et al., "Anti-angiogenic therapy of proliferative diabetic retinopathy," Exp. Opin. Pharmacother. 2:395-407, Ashley Publications Ltd. (March 2001)	
	NPL55 Enholm, B., et al., "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," Trends Cardiovasc. Med. 8:292-297, Elsevier Science Inc. (October 1998)		
	NPL56	Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of Angiogenesis," Recent Progress Hormone Res. 55:15-36, The Endocrine Society (March 2000)	
	NPL57	Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," Crit. Rev. Ther. Drug Carrier Systems 18:299-339, Begall House, Inc. (August 2001)	
	NPL58	Longo, R., et al., "Anti-angiogenic therapy: Rationale, challenges, and clinical studies," Angiogenesis 5:237-256, Kluwer Academic Publishers (January 2002)	
	NPL59	Statutory Declaration of Kari Alitalo, executed on August 14, 2002, and accompanying Exhibits KA-1 and KA-2	
	NPL60	Statutory Declaration of Peter Adrian Walton Rogers, executed on August 9, 2002	
	NPL61	Statutory Declaration of Francis John Ballard, executed on July 16, 2002	
	NPL62	Statutory Declaration of Kari Alitalo, executed on July 16, 2002, and accompanying Exhibit 1	_
$\sqrt{}$	NPL63	Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I-IV	

Examiner	0	Date	
Signature	Loude	Considered	4.7.06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	form 1449/P	то		Complete if Known		
THE THE PROPERTY OF LIBERT TO A STREET A STREET				Application Number	10/023,584	
	ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	December 21, 2001	
				First Named Inventor	Rosen, Craig A.	
STATE				Art Unit	1647	
(Use as many sheets as necessary)		Examiner Name	Landsman, Robert S.			
Sheet	2	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
ne	NPL64	Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002	
	NPL65	Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I-III	
	NPL66	Statutory Declaration of Gary Baxter Cox, executed on March 22, 2002, and accompanying Exhibit GBC-24	
	NPL67	Statutory Declaration of Francis John Ballard, executed on December 12, 2001, and accompanying Exhibit FJB-1	
	NPL68	Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and accompanying Exhibits 1-2	
	NPL69	Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and accompanying Exhibits PAWR1-PAWR14	
	NPL70	Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and accompanying Exhibits JSM1-JSM4	
	NPL71	Statutory Declaration of Nicholas Kim Hayward, executed on December 8, 2000, and accompanying Exhibits NKH1-NKH2	
	NPL72	Statutory Declaration of Jennifer Ruth Gamble, executed on December 12, 2000, and accompanying Exhibits JRG1-JRG3	
	NPL73	Statutory Declaration of Tom Rapoport, executed on December 13, 2000, and accompanying Exhibits TP1-TP2	

Examiner	\wedge	Date	
Signature	Coulse.	Considered	4.7.06
	70.50	1	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1647

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known 10/023,584 **Application Number ELEVENTH SUPPLEMENTAL** December 21, 2001 Filing Date First Named Inventor Rosen, Craig A.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

(Use as many sheets as necessary)				Examiner Name	Landsman, Robert S.
Sheet	3	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

Art Unit

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T²
BL	NPL74	Statutory Declaration of Stuart A. Aaronson, executed on December 14, 2000, and accompanying CV	
	NPL75	Statutory Declaration of Susan Power, executed on December 13, 2000, and accompanying Appendices 1-2 and Figure 1	
	NPL76	Statutory Declaration of Gary Baxter Cox, executed on December 13, 2000, and accompanying Exhibits GBC1-GBC23	
	NPL77	Statutory Declaration of Peter Adrian Walton Rogers, executed on February 16, 2000, and accompanying Exhibit 1	
	NPL78 Statutory Declaration of Francis John Ballard, executed on February 16, 2000, and accompanying Exhibit 1		
	NPL79	Statutory Declaration of Kari Alitalo, executed on February 15, 2000, and accompanying Exhibits 1-3	
	NPL80	Anderson, W.F., "Human gene therapy," Nature 392:25-30, Macmillan Magazines Ltd. (April 1998)	
	NPL81	Maynard, J. and Georgiou, G., "Antibody Engineering," Annu. Rev. Biomed. Eng. 2:339-376, Annual Reviews (August 2000)	
	NPL82	Morea, V., et al., "Antibody Modeling: Implications for Engineering and Design," Methods 20:267-279, Academic Press (March 2000)	
V	NPL83	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors 17</i> :1-11, Taylor & Francis (1999)	

Examiner		Date	
Signature	Double	Considered	4.7.06
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is unique citation designation number (optional).

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, ospirous process) an application. Commissionally is governed by 35 0.3.0. 122 and 37 CPK 1.18. This collection is estimated to take 2 nours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known 10/023,584 Application Number **ELEVENTH SUPPLEMENTAL** Filing Date December 21, 2001 INFORMATION DISCLOSURE First Named Inventor Rosen, Craig A. STATEMENT BY APPLICANT Art Unit 1647 (Use as many sheets as necessary) Landsman, Robert S. Examiner Name 1488.100000Q/HCC/LMB Sheet of Attorney Docket Number

-	l o:	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BL	NPL84	Walsh, D.A., "Angiogenesis and arthritis," <i>Rheumatology 38</i> :103-112, British Society for Rheumatology (February 1999)	
	i		
05837_1.D	OC		
Examiner Signature	i	Packet Date Considered 4.7.06	_

Leitel Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, ospholo by preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

First Named Inventor

Filing Date

Complete if Known

10/023,584

December 21, 2001

Craig A. Rosen

Substitute for form 1449/PTO

Sheet

STATE STATE

NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1647 Art Unit **Examiner Name** Landsman, Robert S. 1488.100000Q/EKS/HCC **Attorney Docket Number** of 3

			U.S. PATENT DO	CUMENTS		
Examiner Cite Initials No.		Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Number-Kind Code ^{2 (If Known)}		Applicant of Ones Document	or Relevant Figures Appear		
BL	US1	5,932,540	08-03-1999	Hu et al.		
	US2	5,935,820	08-10-1999	Hu et al.		
	US3	6,040,157	03-21-2000	Hu et al.		
-V	US4	6,130,071	10-10-2000	Alitalo et al.		
			 			
•			<u> </u>			
						

		FC	REIGN PATENT DO	DCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
	<u></u>	Country Code ¹ Number ⁴ Kind Code ¹ (if known)			Te
BC	FPI	AU-710696	09-30-1999	Genentech, Inc.	
	FP2	EP-0 506477	09-30-1992	Merck & Co., Inc.	1
	FP3	WO-91/02058	02-21-1991	Scios Nova Inc.	1
	FP4	WO-97/00271	01-03-1997	The Regents of the University of California	
	FP5	WO-97/05250	02-13-1997	University of Helsinki	
	FP6	WO-97/08320	03-06-1997	Morphosys Gesellschaft Fur Proteinoptimier Ung MBH	
	FP7	WO-97/09427	03-13-1997	Genentech, Inc.	1
	FP8	WO-97/17442	05-15-1997	Immunex Corporation	1
\mathbf{V}	FP9	WO-97/19694	06-05-1997	Amgen, Inc.	1

Examiner Signature Leckel	Date Considered	4.7.06
---------------------------	--------------------	--------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. • Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. • Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2005.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	Substitute for form 1449/PTO			Complete if Known		
NIENION	T OTT	ODE EX	ATOMITO A T	Application Number	10/023,584	
	NINTH SUPPLEMENTAL INFORMATION DISCLOSURE			Filing Date	December 21, 2001	
-				First Named Inventor	Craig A. Rosen	
STAT	EME	NT BY	APPLICANT	Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	Landsman, Robert S.	
Sheet	2	of	3	Attorney Docket Number	1488.100000Q/EKS/HCC	

	U.S. PATENT DOCUMENTS							
Examiner Cite	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages			
Initials* No.1		Number-Kind Code ^{2 (If Known)}	MM-DD-TTTT	Applicant of Cited Document	or Relevant Figures Appear			
			<u> </u>					
			ļ					
								
			 					
			 					
								
	· · · · · · · · · · · · · · · · · · ·							
					-			
•								

	•		FOREIGN PATENT DO	DCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T⁵
BL	FP10	WO-98/06844	02-19-1998	Human Genome Sciences, Inc.	
	FP11	WO-98/24811	06-11-1998	Zymogenetics, Inc.	
	FP12	WO-98/39035	09-11-1998	The Wistar Institute of Anatomy & Biology	
	FP13	WO-98/49300	11-05-1998	Collateral Therapeutics	
	FP14	WO-98/55619	12-10-1998	ASAT AG Applied Science & Technology	
	FP15	WO-98/56936	12-17-1998	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	
	FP16	WO-99/02545	01-21-1999	Novopharm Biotech, Inc.	
	FP17	WO-99/08522	02-25-1999	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	
<u> </u>	FP18	WO-99/20749	04-29-1999	Medical Research Council	

Examiner		Date	
Signature	Loude	Considered	4.7.06
			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. • Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST.16 if possible. • Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute t	Substitute for form 1449/PTO			Complete if Known	
SITSIMI			ADDRIVED A X	Application Number	10/023,584
			MENTAL	Filing Date	December 21, 2001
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor	Craig A. Rosen
STATE				Art Unit	1647
	(Use as	many she	ets as necessary)	Examiner Name	Landsman, Robert S.
Sheet	3	of	3	Attorney Docket Number	1488.100000Q/EKS/HCC

		·	U.S. PATENT DOG	CUMENTS	
Examiner Cite Initials No.		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appea	
	<u> </u>				
			 - 		
					- -
					
·					
	<u> </u>				
	 				
	-				
			 		
	l				

			FOREIGN PATENT DO		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	1
Initials* No.1	Country Code ³ Number ⁴ Kind Code ³ (if known)	MM-DD-YYYY	Applicant of Cited Document	т	
BL	FP19	WO-99/21590	05-06-1999	Merck & Co.	
	FP20	WO-00/73430-A3	12-07-2000	Max-Delbrueck Centrum Fur Molekulare Medizin	
	FP21	WO-00/75163	12-14-2000	Human Genome Sciences, Inc.	
	FP22	WO-01/57226-A1	08-09-2001	Millennium Pharmaceuticals, Inc.	
- $$	FP23	WO-01/58956-A3	08-16-2001	BASF Aktiengesellschaft	
			<u> </u>		+
			7		

Examiner		Date	
Signature	laise	Considered	4.7.06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

December 21, 2001

10/023,584

1647

Craig A. Rosen

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. ostitute for form 1449/PTO Complete if Known

Application Number

First Named Inventor

Filing Date

Art Unit

NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Landsman, Robert S. **Examiner Name** Attorney Docket Number 1488.100000Q/EKS/HCC Sheet of 3

		Non Patent Literature Documents			
Examiner Initials* Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title o the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published			
		ALTSHULER et al., "Taurine promotes the differentiation of a vertebrate retinal cell type in vitro," Development 119:1317-1328, The Company of Biologists Limited (December 1993)			
	NPL2	BOCKER-MEFFERT et al., "Erythropoietin and VEGF Promote Neural Outgrowth from Retinal Explants in Postnatal Rats," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:2021-2026, Association for Research in Vision and Ophthalmology (June 2002)			
	NPL3	GERHARDINGER et al., "Expression of Vascular Endothelial Growth Factor in the Human Retina and in Nonproliferative Diabetic Retinopathy," Am. J. Pathol. 152:1453-1462, American Society for Investigative Pathology (June 1998)			
,	NPL4	HANNINK et al., "Deletions in the C-Terminal Coding Region of the v-sis Gene: Dimerization Is Required for Transformation" Mol. And Cellular Biol. 6:1304-1314, American Society for Microbiology (1986)			
	NPL5	HIRAI et al., "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endometrial Carcinoma," Gynecol. Oncol. 80:181-188, Academic Press (February 2001)			
	NPL6	KELLEY et al., "Regulation of a Proliferation and Photoreceptor Differentiation in Fetal Human Retinal Cell Cultures," Invest. Ophthalmol. Vis. Sci. 36:1280-1289, Association for Research in Vision and Ophthalmology (June 1995)			
	NPL7	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: The Protein Folding Problem and Tertiary Structure Prediction, Kenneth Merz, Jr. and Scott LeGrand, eds., Birkhauser, Boston, MA, pp. 491-495 (January 1994)			
	NPL8	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," Proc. Natl. Acad. Sci. USA, 79:1979-1983, National Academy of Science (1982)			
	NPL9	SCHLAEPPI et al., "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor." J. Cancer Res. Clin. Oncol. 125:336-342, Springer-Verlag (June 1999)			
	NPL10	SCHRATZBERGER et al., "Reversal of experimental diabetic neuropathy by VEGF gene transfer," J. Clin. Invest. 107:1083-1092, American Society for Clinical Investigation (May 2001)			

Examiner		Date	
Signature	Loubl	Considered	4.7.06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

*EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for fe	Substitute for form 1449/PTO			Co	Complete if Known		
NINTH SUPPLEMENTAL		Application Number	10/023,584				
		Filing Date	December 21, 2001				
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Craig A. Rosen			
			Art Unit	1647			
(Examiner Name	Landsman, Robert S.			
Sheet	2	of	3	Attorney Docket Number	1488.100000Q/EKS/HCC		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T²
BC NPL11		SCHULZ-KEY et al., "Ciliary Neurotrophic Factor as a Transient Negative Regulator of Rod Development in Rat Retina," Invest. Ophthalmol. Vis. Sci. 43:3099-3108, Association for Research in Vision and Ophthalmology (September 2002)	
	NPL12	STACKER et al., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," Growth Factors 17:1-11, Harwood Academic Publishers (March 1999)	
	NPL13	VALE et al., "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1 (VEGF2) in an Animal Model of Chronic Myocardial Ischemia," Circulation (Supplement), 100:I-22, Lippincott, Williams & Wilkins (November 1999)	
	NPL14	VALE et al., "Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients with Chronic Myocardial Ischemia," Circulation, 103:17:2138-2143, Lipincott, Williams & Wilkins (May 2001)	
	NPL15	VAN DER FLIER et al., "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis." J. Neuroimmunol. 160:170-177, Elsevier B.V. (March 2005)	
	NPL16	VERMA et al., "Gene therapy promises, problems and prospects," Nature 389:239-242, Nature Publishing Company (September 1997)	
	NPL17	WINKLER et al., "Changing the antigen binding specificity by single point mutations of an Anti-p24 (HIV-1) antibody." J. Immunol. 165:4505-4514, The American Association of Immunologists (October 2000)	
	NPL18	YANG et al., "Flk-1, a Receptor for Vascular Endothelial Growth Factor (VEGF), Is Expressed by Retinal Progenitor Cells," J. Neurosci. 16:6089-6099, Society for Neuroscience (October 1996)	
	NPL19	GenBank Accession No. S08167, PAULSSON et al., "Balbiani ring 3 protein - midge (Chironomus tentans)," (first available April 1993 and last updated July 2000)	
<u> </u>	NPL20	NCBI Entrez, GenBank Report, Accession NO. AF010302, MANDRIOTA, S.J. and PEPPER, M.S. (first available and last updated July 1997)	

	<u></u>		
Examiner Signature	Carre	Date Considered	4.7.06
	Sacra-	Constacted	· -

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	Substitute for form 1449/PTO			Complete if Known		
NINTH SUPPLEMENTAL				Application Number	10/023,584	
				Filing Date	December 21, 2001	
INFORMATION DISCLOSURE				First Named Inventor	Craig A. Rosen	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1647			
		Examiner Name	Landsman, Robert S.			
Sheet	3	of	3	Attorney Docket Number	1488.100000Q/EKS/HCC	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	Т	
M	NPL21	EBI Accession No. AAW27553, KNAPPIK et al., "Human Ab heavy chain variable region VH3 consensus" (January 1998)		
BL	NPL22	YOUREY et al., "Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells," Molec. Biol. Cell. 10:39a, Abstract No. 227, American Society of Microbiology (November 1999)		
,	·			

Examiner	0 0	Date	
Signature	Loube	Considered	4.7.06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through cuation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is not considered to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.